The 2026 drug pipeline is poised to be transformative for both clinical and employer health plans. Breakthrough therapies, including glucagon-like peptide-1s (GLP-1s), gene therapies, and a wave of biosimilars, are set to reshape treatment landscape while creating new cost pressure. U.S. employers face one of the steepest rises in health insurance costs in 15 years, with premiums projected to climb 10% in 2026, making proactive benefit strategy more critical than ever.
Download our white paper to explore:
- Proactive pharmacy benefit strategies
- Emerging treatment categories
- Benefit design and utilization management
